Navigation Links
Rigel to Present at Three Upcoming Investor Conferences
Date:2/28/2011

SAN FRANCISCO, Feb. 28, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at three investment conferences during the month of March.  Details of each conference are as follows:Citi Global Health Care ConferenceDate:  Wednesday, March 2nd at 1:30 p.m. ETLocation:  New York, NY Cowen and Company 31st Annual Health Care ConferenceDate:  Tuesday, March 8th at 1:20 p.m. ETLocation:  Boston, MA Barclays Capital Global Healthcare ConferenceDate:  Thursday, March 17th at 10:45 a.m. ETLocation:  Miami Beach, FLAll three presentations will be webcast.  To access live audio webcast or subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for RA (with AstraZeneca), and R343, an inhaled syk inhibitor in clinical trials for asthma (with Pfizer).

Contact: Ryan MaynardPhone: 650.624.1284Email: invrel@ri
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigel Announces Participation at Two Investor Conferences
2. Rigel to Present at JP Morgan Healthcare Conference
3. Rigel Announces Third Quarter 2009 Financial Results
4. Rigel Announces Presentations at Two Investor Conferences
5. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
6. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
7. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
8. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
9. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
10. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
11. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... former senior vice president and corporate controller, has been ... effective immediately, replacing Peggy Mulligan, former chief financial officer, ... other interests.  The Company has initiated a search to ...
... (Nasdaq: STXS ) announced today that the Company ... which includes a $30 million revolving facility that matures on ... matures on December 31, 2013.  The new facility was led ... that was scheduled to mature in March 2011. ...
Cached Medicine Technology:Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... a competitive application process, Michele D. Kipke, PhD, Vice ... Hospital Los Angeles, was awarded a $420,000 grant which ... Autism Treatment Network (ATN) as an ATN Center of ... Speaks, which is North America,s largest autism science and ...
... hemorrhagic fever in humans, has no known cure or vaccine. ... scientists has uncovered a family of small molecules which appear ... inhibit its entry into human cells. The results are ... and are now online. Previous studies have shown ...
... discovered that cells lining the blood vessels secrete molecules ... invading other tissues, a finding that could lead to ... professor in the MIT-Harvard Division of Health Sciences and ... a patient,s tumor could shrink a tumor or prevent ...
... to research conducted at the Oregon National Primate Research Center ... that oral contraceptives cause weight gain appears to be false. ... appear in next month,s edition of the journal Human ... reveal that contraceptives and the possibility that they may cause ...
... WEDNESDAY, Jan. 19 (HealthDay News) -- Many U.S. transplant ... trying to develop new safeguards that would protect and ... one-third of transplant surgeons in the nation "overreacted" to ... contracted HIV after receiving organs from a single donor ...
... a gene that is mutated in one in three patients ... of a frequently mutated gene will provide new insights into ... critical in the continued effort to improve treatment for renal ... to be mutated in 88 cases out of 257 clear ...
Cached Medicine News:Health News:Children's Hospital Los Angeles joins Autism Treatment Network 2Health News:Small molecules may prevent ebola infection 2Health News:MIT scientists discover cancer-fighting role for cells 2Health News:MIT scientists discover cancer-fighting role for cells 3Health News:MIT scientists discover cancer-fighting role for cells 4Health News:Do birth control pills cause weight gain? New research says no 2Health News:Research provides new kidney cancer clues 2Health News:Research provides new kidney cancer clues 3
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: